stoxline Quote Chart Rank Option Currency Glossary
  
Aridis Pharmaceuticals, Inc. (ARDS)
0.0001  0 (0%)    02-11 15:00
Open: 0.01
High: 0.01
Volume: 200
  
Pre. Close: 9.9999997E-5
Low: 0.0001
Market Cap: 0(M)
Technical analysis
2025-02-12 4:43:03 PM
Short term     
Mid term     
Targets 6-month :  0 1-year :  0.01
Resists First :  0 Second :  0
Pivot price 0
Supports First :  0 Second :  0
MAs MA(5) :  0 MA(20) :  0
MA(100) :  0 MA(250) :  0.02
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  0 D(3) :  0
RSI RSI(14): 32.5
52-week High :  0.08 Low :  0
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ARDS ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.01 - 0.01 0.01 - 0.01
Low: 0 - 0 0 - 0
Close: 0 - 0 0 - 0
Company Description

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Headline News

Fri, 20 Dec 2024
Aridis Provides Corporate Update - GlobeNewswire

Fri, 28 Jun 2024
Aridis Pharmaceuticals CEO buys $50,000 in company stock - Investing.com

Mon, 24 Jun 2024
Aridis Provides Corporate Update - GlobeNewswire

Wed, 12 Jul 2023
Aridis’ AR-301 Monoclonal Antibody is Among the First - GlobeNewswire

Tue, 14 Mar 2023
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session By Benzinga - Investing.com UK

Tue, 04 Oct 2022
Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 45 (M)
Shares Float 37 (M)
Held by Insiders 18 (%)
Held by Institutions 10.3 (%)
Shares Short 2,000 (K)
Shares Short P.Month 440 (K)
Stock Financials
EPS -0.16
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.26
Profit Margin -5.2 %
Operating Margin -208.4 %
Return on Assets (ttm) -4.5 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 4.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.5
EBITDA (p.s.) -0.01
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.01
Price to Sales 0
Price to Cash Flow -0.01
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android